A phase II study of ALLN-177 in adolescents and adults with primary hyperoxaluria or severe forms of secondary hyperoxaluria
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2018
At a glance
- Drugs ALLN 177 (Primary)
- Indications Primary hyperoxaluria
- Focus Therapeutic Use
- 04 Jan 2018 Status changed from planning to not yet recruiting.
- 20 Dec 2017 New trial record
- 14 Dec 2017 According to an Allena Pharmaceuticals media release, the company plans to initiate this study in the first quarter of 2018, with interim data expected in the second half of 2018.